EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer

Luke Steventon iD, Kenneth K C Man iD, Shibani Nicum iD, Rowan E Miller iD, Shira Peleg Hasson iD, Samixa Shah, Michael Baser, Emma Kipps iD, Martin D Forster, Ofran Almossawi, Pinkie Chambers iD

The Oncologist · 04.11.2024 · 29 (11) · e1532-e1539

DOI: 10.1093/oncolo/oyae201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 07.09.2024. Verfasst von Luke Steventon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department and Centre of Medicines Optimization Research and Education (CMORE), University College Hospitals NHS Foundation Trust, 2…. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Research for Patient Benefit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chemotherapy forms the cornerstone of systemic treatment for advanced ovarian cancer, extending overall survival; however, drug-related toxicity can lead to treatment delays, potentially diminishing treatment efficacy. This study evaluated the impact of treatment delays on all-cause mortality of patients with ovarian cancer, to better inform decisions on patient management.

Methods

This retrospective, population-based cohort study included 1517 women with advanced-stage ovarian cancer, receiving first-line adjuvant or neoadjuvant chemotherapy in 2014 and 2015. The frequency of inter-cycle delays >7 days was calculated using drug administration dates. Kaplan-Meier estimates were used to compare 2-year overall survival (OS) between patients who were delayed and those treated to schedule. Cox proportional hazards regression was used to investigate the impact of treatment delay on all-cause mortality. Inverse probability of treatment weighting propensity scores were used to adjust for confounding variables.

Results

Delays >7 days occurred in 35.3% of patients. Two-year OS probability was 62.7% in patients who experienced treatment delays >7 days (95% CI, 58.7-66.9) compared to 69.1% in those treated to schedule (95% CI, 66.2-72.0). Delays were not significantly associated with all-cause mortality when adjusted for confounders (HR 1.00 95% CI, 0.83-1.20, P = .9).

Conclusions

Delays to chemotherapy treatment were not significantly associated with worsened survival in patients with advanced-stage ovarian cancer. These results can inform clinical decision making that prioritize toxicity management and quality of life for those treated with chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsHumansFemaleMiddle AgedRetrospective StudiesAgedNeoplasm StagingTime-to-TreatmentChemotherapy, AdjuvantAdultAntineoplastic Combined Chemotherapy ProtocolsTreatment Delay

Stichwörter der Autor:innen

cancerchemotherapydelayovariansurvivaltreatment

Autor:innen und Institutionen

  • Medical Oncology Department and Centre of Medicines Optimization Research and Education (CMORE), University College Hospitals NHS Foundation Trust, 235 Euston rd, London NW1 2PP, United Kingdom.
  • Department of Practice and Policy, UCL School of Pharmacy, London WC1H 9JP, United Kingdom.
  • UCL Cancer Institute, Department of Oncology, London WC1 6DD, United Kingdom.
  • School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • The Royal Marsden NHS Trust, London SW3 6JJ, United Kingdom.
  • National Disease Registration Service (NDRS), NHS England, London E14 4PU, United Kingdom.

ORCID-Profile: Luke Steventon, Kenneth K C Man, Shibani Nicum, Rowan E Miller, Shira Peleg Hasson, Emma Kipps, Pinkie Chambers

Förderung

  • National Institute for Health and Care Research
  • Research for Patient Benefit

Zitieren

APA

Steventon, L., Man, K. K. C., Nicum, S., Miller, R. E., Peleg Hasson, S., Shah, S., Baser, M., Kipps, E., Forster, M. D., Almossawi, O., & Chambers, P. (2024). The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist, 29(11), e1532-e1539. https://doi.org/10.1093/oncolo/oyae201

Vancouver

Steventon L, Man KKC, Nicum S, Miller RE, Peleg Hasson S, Shah S, et al. The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer. The Oncologist. 2024;29(11):e1532-e1539. doi:10.1093/oncolo/oyae201

BibTeX
@article{Steventon2024,
  author = {Steventon, Luke and Man, Kenneth K C and Nicum, Shibani and Miller, Rowan E and Peleg Hasson, Shira and Shah, Samixa and Baser, Michael and Kipps, Emma and Forster, Martin D and Almossawi, Ofran and Chambers, Pinkie},
  title = {The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancer},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {11},
  pages = {e1532--e1539},
  doi = {10.1093/oncolo/oyae201}
}
Kostenlos starten →